Phase Ii and Pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 701-707

  Broniscer, Alberto ^a   Baker, Suzanne J ^a   Stewart, Clinton F ^a   Merchant, Thomas E ^a   Laningham, Fred H ^a   Schaiquevich, Paula ^a   Kocak, Mehmet ^a   Morris, E Brannon ^a   Endersby, Raelene ^a   Ellison, David W ^a   Gajjar, Amar ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; OSI 420; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; ANTICONVULSIVE AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADOLESCENT; ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG ERUPTION; ELECTROLYTE DISTURBANCE; FATIGUE; FEMALE; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; INFECTION; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PRURITUS; RADIATION DOSE; RASH; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; BRAIN TUMOR; MULTIMODALITY CANCER THERAPY;

ADOLESCENT; ADULT; ANTICONVULSANTS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; GLIOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; YOUNG ADULT;

EID: 59449092893     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1923     Document Type: Article

References (41)

1. Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 2004;9:197 - 206.
2. Stupp R, Mason WP, Van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
3. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 2002;20:4684-91.
4. Broniscer A, Chintagumpala M, Fouladi M, et al. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol 2006;76:313-9.
5. Ruggiero A, Cefalo G, Garré ML, et al. Phase II trial of temozolomide in children with recurrent high-grade glioma. J Neurooncol 2006;77:89-94.
6. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 2007;110:1542-50.
7. Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 2007;6:1909-19.
8. Rickert CH, Sträter R, Kaatsch P, et al. Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol 2001;158:1525-32.
9. Pollack IF, Hamilton RL, James CD, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg 2006;105:418 - 24.
10. Faury D, Nantel A, Dunn SE, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 2007;25:1196-208.
11. Bredel M, Pollack IF, Hamilton RL, et al. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 1999;5:1786-92.
12. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311 -33.
13. Raffel C, Frederick L, O'Fallon JR, et al. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 1999;5:4085-90.
14. Korshunov A, Sycheva R, Gorelyshev S, et al. Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod Pathol 2005;18:1258-63.
15. Chakravarti A, ChakladarA, Delaney MA, et al.The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002;62:4307-15.
16. Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 2006;12:2264-71.
17. Prados MD, Lamborn KR, Chang S, et al. Phase 1 study of erlotinib HCI alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncol 2006;8:67-78.
18. Cloughesy TF, Yung WA,Vrendenberg K, et al. Phase II study of erlotinib in recurrent GBM: molecular predictors of outcome. J Clin Oncol 2005;23:115s (suppl; abstr 1507).
19. Vogelbaum MA, Peereboom DM, Stevens G, et al. Phase II study of erlotinib single agent therapy in recurrent glioblastoma multiforme. Eur J Cancer 2005;3:135 (suppl; abstr 486).
20. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79.
21. Broniscer A, Panetta JC, O'Shaughnessy M, et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 2007;13:1511 -5.
22. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
23. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-40.
24. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
25. Fraser MM, Zhu X, Kwon CH, Uhlmann EJ, Gutmann DH, Baker SJ. Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res 2004;64:7773-9.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958:53:457-81.
27. Peto R, Pike MC, Armitage P, et al. Design and anal-ysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612.
28. Jakacki Rl.Tersak J, Blaney S, et al. A pediatric phase I trial and pharmacokinetic (PK) study of erlotinib (ERL) followed by the combination of ER L with temozolomide (TMZ): a Children's Oncology Group Study. J Clin Oncol 2006;24:18s (suppl; abstract 9015).
29. Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006;12:2166-71.
30. Jackman DM, Yeap BY, Lindeman Nl, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760-6.
31. Duran I, Hotté SJ, Hirte H, et al. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 2007;13:4849 - 57.
32. Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 2004;6:520-3.
33. Rich JN, Rasheed BK, Yan H. EGFR mutations and sensitivity to gefitinib. N Engl J Med 2004;351:1260-1.
34. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer lnst2005;97:880-7.
35. Lassman AB, Rossi MR, Razier JR, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor ConsortiumTrials 01-03 and 00-01. Clin Cancer Res 2005;11:7841 -50.
36. Mellinghoff IK, Wang MY,Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24.
37. Marie Y, Carpentier AF, Omuro AM, et al. EGFR tyrosine kinase domain mutations in human gliomas. Neurology 2005;64:1444-5.
38. Lee JC, Vivanco I, Beroukhim R, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 2006;3:e485.
39. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
40. Gallia GL, Rand V, Siu IM, et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 2006;4:709-14.
41. Hartmann C, Bartels G, Gehlhaar C, Holtkamp N, von Deimling A. PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol (Berl) 2005;109:639-42.